Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07-based regimens in advanced hepatocellular carcinoma
CTR20222315Phase 2Terminated
- Sponsor
- Fosun Pharma
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pimurutamab in hepatocellular carcinoma (HCC), sponsored by Fosun Pharma. Started Sep 2022; status: terminated.
02
Drugs
pimurutamab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20222315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222315.